Research & Development
US government signs USD2.94bn deal to purchases 1.4 million additional doses of Regeneron's COVID-19 antibody therapy
15 September 2021 -

US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) has signed a deal with the US government for purchase of 1.4 million additional doses of the company's COVID-19 antibody cocktail, REGEN-COV, Reuters news agency reported on Wednesday.

This cocktail, a combination of antibodies casirivimab and imdevimab, was authorised in November for emergency use by the US Food and Drug Administration (FDA).

According to the company, which completed its initial contract with the US government of supplying 1.5 million doses in the second quarter, it would supply the additional doses by 31 January 2022 at a cost of USD2,100 per dose. This values the latest contract at USD2.94bn.



Related Headlines